This company seems to have been delisted
Reason: Filed for bankruptcy
Last recorded trade on: June 22, 2023
Source: https://www.bloomberg.com/news/articles/2023-05-03/generic-drugmaker-lannett-files-for-chapter-11-bankruptcy
Reason: Filed for bankruptcy
Last recorded trade on: June 22, 2023
Source: https://www.bloomberg.com/news/articles/2023-05-03/generic-drugmaker-lannett-files-for-chapter-11-bankruptcy
Lannett Company
LCI
NZ$1.14
Share price
0.00%
Change (1 day)
-69.37%
Change (1 year)
Categories
Lannett Company (LCI) - Total liabilities
Total liabilities on the balance sheet as of March 2023 : NZ$1.24 Billion
According to Lannett Company's latest financial reports the company's total liabilities are NZ$1.24 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Lannett Company - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-06-30 | NZ$1.17 B | 15.95% |
| 2021-06-30 | NZ$1.01 B | -21.34% |
| 2020-06-30 | NZ$1.29 B | 1.81% |
| 2019-06-30 | NZ$1.26 B | -11.96% |
| 2018-06-30 | NZ$1.44 B | 1.28% |
| 2017-06-30 | NZ$1.42 B | -16.01% |
| 2016-06-30 | NZ$1.69 B | 2456.38% |
| 2015-06-30 | NZ$66.3 M | 21.02% |
| 2014-06-30 | NZ$54.78 M | 8.86% |
| 2013-06-30 | NZ$50.32 M | -13.89% |
| 2012-06-30 | NZ$58.44 M | 15.13% |
| 2011-06-30 | NZ$50.76 M | -31.15% |
| 2010-06-30 | NZ$73.73 M | 0.74% |
| 2009-06-30 | NZ$73.2 M | 17.15% |
| 2008-06-30 | NZ$62.48 M | 39.34% |
| 2007-06-30 | NZ$44.84 M | -10.18% |
| 2006-06-30 | NZ$49.92 M | 33.04% |
| 2005-06-30 | NZ$37.52 M | 15.55% |
| 2004-06-30 | NZ$32.47 M | 153.3% |
| 2003-06-30 | NZ$12.82 M | -10.24% |
| 2002-06-30 | NZ$14.28 M | -55.84% |
| 2001-06-30 | NZ$32.34 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$195.08 B | 15,617.46% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$192.04 B | 15,372.57% | 🇺🇸 USA |
 Abbott Laboratories ABT | NZ$53.81 B | 4,235.89% | 🇺🇸 USA |
 Novartis NVS | NZ$102.18 B | 8,132.75% | 🇨🇭 Switzerland |
 GlaxoSmithKline GSK | NZ$101.02 B | 8,039.71% | 🇬🇧 UK |